Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-06-28FDA Approved: USTEKINUMAB-TTWE — Original Application (Quallent Pharmaceuticals Health LLC)
FDA approves a new biologic product, ustekinumab-tTWE, from Quallent Pharmaceuticals Health LLC, via an Original Biologics License Applicati…
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis [Phase 2]
Phase 2 trial evaluating the efficacy and safety of ME3183 in adults with moderate to severe plaque psoriasis; results have been posted (Jun…
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating HB0017 for efficacy and safety in moderate to severe plaque psoriasis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-06-21Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis [Phase 2]
A completed Phase 2 study assessing the efficacy and safety of HB0017 in adults with moderate to severe plaque psoriasis.
-
CLINICAL_TRIALS trial_result · 2024-06-14Clinical Trial Update: Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement [Phase 3]
This is a Phase 3 clinical trial evaluating subcutaneous risankizumab for adults with moderate-to-severe plaque psoriasis involving the palm…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-06-14Clinical Trial Update: A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices [Phase 1]
Phase 1 study evaluating the safety and pharmacokinetics of SHR-1314 injection in healthy subjects across different device specifications; t…
-
CLINICAL_TRIALS trial_result · 2024-06-05Clinical Trial Update: Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain
A completed real-world study in Spain evaluating the benefits of apremilast for plaque psoriasis in patients who have received prior systemi…
-
CLINICAL_TRIALS trial_result · 2024-06-04Clinical Trial Update: Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis [Phase 3]
A Phase 3 open-label study evaluating the safety and efficacy of AK101 injections for plaque psoriasis has completed.
-
CLINICAL_TRIALS research · 2024-05-02Clinical Trial Update: A Multicentre Randomized Controlled Clinical Study on the Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment Therapy for Psoriasis With Blood Stasis Syndrome. [Phase 1]
A multicenter Phase 1 randomized study is evaluating the safety of the Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment for plaque pso…
-
FDA approval · 2024-04-30FDA Approved: ABRILADA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for ABRILADA (adalimumab-afzb) from Pfizer Laboratories Div Pfizer Inc, authorizing its use as a…
-
CLINICAL_TRIALS trial_result · 2024-04-30Clinical Trial Update: An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque Psoriasis [Phase 2]
Phase 2 study of SYHX1901 tablets for moderate to severe plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2024-04-30Clinical Trial Update: Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy [Phase 4]
A Phase 4 head-to-head clinical trial comparing subcutaneous risankizumab to oral apremilast in adults with moderate plaque psoriasis; the t…
-
CLINICAL_TRIALS trial_result · 2024-04-29Clinical Trial Update: A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea [Phase 3]
A Phase 3 study of brodalumab (KHK4827) for moderate to severe plaque psoriasis in Korea has been completed.
-
FDA approval · 2024-04-25FDA Approved: OTEZLA — Supplemental Application (Amgen, Inc)
The FDA approved Amgen's supplemental application for OTEZLA (apremilast), resulting in an approved supplemental change to the product label…
-
CLINICAL_TRIALS research · 2024-04-25Clinical Trial Update: A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
A study conducted in Japan is evaluating the comparative effectiveness of deucravacitinib in adults with plaque psoriasis. The trial is curr…
-
FDA approval · 2024-04-16FDA Approved: SELARSDI — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approved SELARSDI (USTEKINUMAB-AEKN) from Teva Pharmaceuticals USA, Inc. under an original Biologics License Application (BLA 761343).
-
FDA approval · 2024-04-03FDA Approved: ILUMYA — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for ILUMYA (tildrakizumab-asmn) filed by Sun Pharmaceutical Industries, expanding or modifying its r…
-
CLINICAL_TRIALS trial_result · 2024-03-25Clinical Trial Update: Combination of Sotyktu and Enstilar for Plaque Psoriasis [Phase 4]
Phase 4 clinical trial evaluating the combination of Sotyktu and Enstilar for plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis [Phase 3]
A Phase 3 study update reporting efficacy and safety results of bimekizumab in adult Korean participants with moderate to severe plaque psor…
-
FDA approval · 2024-03-18FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab submitted by Janssen Biotech, Inc.
-
CLINICAL_TRIALS trial_result · 2024-03-08Clinical Trial Update: An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO [Phase 3]
Phase III study update for a recombinant anti-IL-17A monoclonal antibody in Chinese patients with plaque psoriasis.
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis [Phase 3]
Phase 3 trial results (efficacy and safety) for brodalumab in adolescents aged 12 to 17 with moderate-to-severe plaque psoriasis; the study …
-
FDA approval · 2024-02-22FDA Approved: ZYMFENTRA — Supplemental Application (CELLTRION USA Inc.)
The FDA approved a supplemental application for ZYMFENTRA (infliximab-dyyb) submitted by Celltrion USA Inc.
-
CLINICAL_TRIALS trial_result · 2024-02-09Clinical Trial Update: A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial comparing ABP 501 with Humira in moderate to severe plaque psoriasis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-02-08Clinical Trial Update: A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD) [Phase 3]
Phase 3 trial evaluating Secukinumab for plaque psoriasis with coexisting NAFLD was terminated; results have been posted.